Search Results 1721-1730 of 14774 for anti-TNF drugs

1. Study of RP-3500 With Niraparib or Olaparib in Advanced Solid Tumors - Mayo Clinic

   Drugs & Supplements A-Z · Health Books · Healthy ... By condition, treatment or drug name. Search tips ... anti-tumor activity. Participation eligibility.

2. A Study to Evaluate Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Patients - Mayo Clinic

   About this study. The purpose of this study is to evaluate, jointly and independently among patients deemed at higher risk vs. lower risk for disability ...

3. Fulvestrant (Intramuscular Route) Before Using - Mayo Clinic

   Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Drug Interactions. Although certain medicines should ...

4. Publications - Sean S. Park, M.D., Ph.D. - Mayo Clinic

   Drugs & Supplements · Healthy Lifestyle · Books ... Synthesis and evaluation of anti-PD-L1-B11 ... Minibeam Radiation Therapy Treatment (MBRT): Commissioning and ...

5. Daratumumab And Hyaluronidase-Fihj (Subcutaneous Route) Description and Brand Names - Mayo Clinic

   Drugs and Supplements · Daratumumab And Hyaluronidase-Fihj (Subcutaneous Route) ... treatment) multiple myeloma in patients who have received at least 1 previous ...

6. Nilotinib (Oral Route) Description and Brand Names - Mayo Clinic

   Nilotinib belongs to the general group of medicines known as antineoplastics or cancer medicines. It interferes with the growth of cancer cells, ...

7. Estradiol (Transdermal Route) Description and Brand Names - Mayo Clinic

   Description and Brand Names. Drug information provided by: Merative, Micromedex®. US Brand Name. Alora; Climara; Divigel; Elestrin; Esclim; Estraderm ...

8. A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis - Mayo Clinic

   Participation eligibility · Any anti-CD20 therapy such as rituximab, ocrelizumab, or ofatumumab less than 9 months prior to screening or during screening; · If an ...

9. Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) - Mayo Clinic

   antidiabetic drugs, change in anti-diabetic therapy must follow these requirements: no qualitative change 6 months prior to diagnostic liver biopsy up to ...

10. Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia - Mayo Clinic

    By condition, treatment or drug name. Search ... Drugs used in chemotherapy work in different ways ... anti-positivity. No prior therapy except for ...